Novo Nordisk’s blockbuster weight-loss drug cuts the risk of kidney disease-related events in diabetic patients by 24%, according to a new clinical trial conducted by the company.
Trending
- Long before AI, fake photos were already popular
- War and creativity: Lebanese artists reflect on crisis
- Woman arrested on suspicion of attempted murder after shots fired at Rihanna’s LA home | US News
- Trump trying to gauge whether new ayatollah is 'a leader he can work with'
- Rivalry tests Merz and German economy
- One in three Gen Z men want obedient women
- Grok posts about fatal football disasters ‘sickening’, says government | Science, Climate & Tech News
- Mayor Sadiq Khan invites embattled AI firm Anthropic to expand in London
